Treatment and outcomes of minor salivary gland cancers of the larynx and trachea: a systematic review.

IF 2.1 4区医学 Q2 OTORHINOLARYNGOLOGY

Acta Otorhinolaryngologica Italica Pub Date : 2023-12-01 Epub Date: 2023-10-10 DOI:10.14639/0392-100X-N2635

Claudia Montenegro, Davide Mattavelli, Davide Lancini, Alberto Paderno, Elisa Marazzi, Vittorio Rampinelli, Michele Tomasoni, Cesare Piazza

{"title":"Treatment and outcomes of minor salivary gland cancers of the larynx and trachea: a systematic review.","authors":"Claudia Montenegro, Davide Mattavelli, Davide Lancini, Alberto Paderno, Elisa Marazzi, Vittorio Rampinelli, Michele Tomasoni, Cesare Piazza","doi":"10.14639/0392-100X-N2635","DOIUrl":null,"url":null,"abstract":"Objectives: Malignant minor salivary glands carcinomas (MiSGC) of the larynx and trachea are rare tumours and published evidence is sparse. We conducted a systematic review to describe shareable treatment strategies and oncological outcomes of these neoplastic entities.Methods: Full text English manuscripts published from January 1st 2000 to December 14th 2022 were included. Data on demographics, treatments and outcomes were collected. A pooled analysis of 5-year overall survival (OS) was performed.Results: Seventeen articles and 365 patients met the inclusion criteria. The most common subsites involved were subglottic and distal trachea. Adenoid cystic carcinoma was, by far, the most frequent histotype. The first-choice treatment strategy was surgery (86.8%), while adjuvant treatments were delivered in 57.4% of patients. Only 12.9% were treated with definitive radiotherapy with/without chemotherapy. The mean follow-up was 68.3 months. One hundred nine (34.9%) deaths were recorded and 62.4% were cancer-related. Five-year OS ranged from 20% to 100% and, at pooled analysis, it was 83% (range, 78-87%).Conclusions: In case of MiSGC of the larynx and trachea, surgery remains the mainstay of treatment. Adjuvant treatments are frequently delivered. Survival estimates are good overall, but highly heterogeneous.","PeriodicalId":6890,"journal":{"name":"Acta Otorhinolaryngologica Italica","volume":" ","pages":"365-374"},"PeriodicalIF":2.1000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10773543/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Otorhinolaryngologica Italica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14639/0392-100X-N2635","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Malignant minor salivary glands carcinomas (MiSGC) of the larynx and trachea are rare tumours and published evidence is sparse. We conducted a systematic review to describe shareable treatment strategies and oncological outcomes of these neoplastic entities.

Methods: Full text English manuscripts published from January 1^st 2000 to December 14^th 2022 were included. Data on demographics, treatments and outcomes were collected. A pooled analysis of 5-year overall survival (OS) was performed.

Results: Seventeen articles and 365 patients met the inclusion criteria. The most common subsites involved were subglottic and distal trachea. Adenoid cystic carcinoma was, by far, the most frequent histotype. The first-choice treatment strategy was surgery (86.8%), while adjuvant treatments were delivered in 57.4% of patients. Only 12.9% were treated with definitive radiotherapy with/without chemotherapy. The mean follow-up was 68.3 months. One hundred nine (34.9%) deaths were recorded and 62.4% were cancer-related. Five-year OS ranged from 20% to 100% and, at pooled analysis, it was 83% (range, 78-87%).

Conclusions: In case of MiSGC of the larynx and trachea, surgery remains the mainstay of treatment. Adjuvant treatments are frequently delivered. Survival estimates are good overall, but highly heterogeneous.

查看原文本刊更多论文

喉和气管小涎腺癌的治疗和结果：一项系统综述。

目的：喉和气管的恶性小唾液腺癌（MiSGC）是罕见的肿瘤，已发表的证据很少。我们进行了一项系统综述，以描述这些肿瘤实体的可共享治疗策略和肿瘤学结果。方法：收录2000年1月1日至2022年12月14日出版的英文全文手稿。收集有关人口统计、治疗和结果的数据。对5年总生存期（OS）进行了汇总分析。结果：17篇文章和365名患者符合纳入标准。最常见的病变是声门下和气管远端。腺样囊性癌是迄今为止最常见的组织类型。首选的治疗策略是手术（86.8%），而57.4%的患者接受了辅助治疗。只有12.9%的患者接受了明确的放疗加/不加化疗。平均随访68.3个月。记录了109例（34.9%）死亡，62.4%与癌症相关。五年OS的范围为20%至100%，综合分析为83%（范围为78%-87%）。结论：对于喉和气管的MiSGC，手术仍然是治疗的主要手段。经常提供辅助治疗。总体而言，生存率的估计是好的，但高度异质性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Otorhinolaryngologica Italica OTORHINOLARYNGOLOGY-

CiteScore

3.40

自引率

10.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Acta Otorhinolaryngologica Italica first appeared as “Annali di Laringologia Otologia e Faringologia” and was founded in 1901 by Giulio Masini. It is the official publication of the Italian Hospital Otology Association (A.O.O.I.) and, since 1976, also of the Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale (S.I.O.Ch.C.-F.). The journal publishes original articles (clinical trials, cohort studies, case-control studies, cross-sectional surveys, and diagnostic test assessments) of interest in the field of otorhinolaryngology as well as clinical techniques and technology (a short report of unique or original methods for surgical techniques, medical management or new devices or technology), editorials (including editorial guests – special contribution) and letters to the Editor-in-Chief. Articles concerning science investigations and well prepared systematic reviews (including meta-analyses) on themes related to basic science, clinical otorhinolaryngology and head and neck surgery have high priority.